Physiology: COX-2 inhibitors and cardiovascular risk

Science

Volumn 336, Issue 6087, 2012, Pages 1386-1387

  Cannon, Christopher P ^a   Cannon, Paul J ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN; ROFECOXIB;

CARBON DIOXIDE; CARDIOVASCULAR DISEASE; DEVELOPMENTAL BIOLOGY; ENZYME ACTIVITY; HEALTH RISK; INHIBITION; INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; PAIN; PRIORITY JOURNAL; SHORT SURVEY; STOMACH ULCER; STROKE; THROMBOCYTE AGGREGATION INHIBITION; VASOCONSTRICTION; VASODILATATION;

EID: 84862287785     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1224398     Document Type: Short Survey

References (13)

1. Y. Yu et al., Sci. Transl. Med. 4, 132ra54 (2012).
2. Y. Cheng et al., Science 296, 539 (2002).
3. C. Bombardier et al., N. Engl. J. Med. 343, 1520, 2, 1528 (2000).
4. R. S. Bresalier et al., N. Engl. J. Med. 352, 1092 (2005).
5. D. Mukherjee, S. E. Nissen, E. J. Topol, JAMA 286, 954 (2001).
6. M. M. Bertagnolli et al., N. Engl. J. Med. 355, 873 (2006).
7. S. D. Solomon et al., Circulation 117, 2104 (2008).
8. L. A. García Rodríquez, A. González-Pérez, BMC Med. 3, 17 (2005).
9. C. P. Cannon et al., Lancet 368, 1771 (2006).
10. B. F. McAdam et al., Proc. Natl. Acad. Sci. U.S.A. 96, 272 (1999).
11. F. Catella-Lawson et al., J. Pharmacol. Exp. Ther. 289, 735 (1999).
12. T. Grosser, S. Fries, G. A. FitzGerald, J. Clin. Invest. 116, 4 (2006).
13. E. M. Antman et al., Circulation 115, 1634 (2007).